Synergy Pharmaceuticals price target lowered to $11 from $15 at Cantor Cantor reduced its target on Synergy as the firm has begun valuing the company as a potential takeover target. The firm believes that larger drug companies have become more aware of the attractiveness of the IBS market. The firm keeps a Buy rating on Synergy.
News For SGYP From The Last 14 Days
Check below for free stories on SGYP the last two weeks.